Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$90.21M+2223.46%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Fabrice Chouraqui
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 407
- Beta
- 0.09
- Country
- NL
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 2.51
Financials
Revenue
$90.21M+2223.5%Net Income
$1.64MEBITDA
$8.75MFree Cash Flow
$-12.77MEPS (diluted)
$0.02Shares Outstanding (diluted)
70.14M+17.1%Operating Expenses
$75.78MCash & Debt
$158.28MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $376.13M | $2.85M | $0.04 |
| 2024 | $297.20M | $-11.84M | $-0.18 |
| 2023 | $245.32M | $-10.55M | $-0.14 |
| 2022 | $205.62M | $13.67M | $0.17 |
| 2021 | $198.87M | $16.00M | $0.23 |
| 2020 | $212.17M | $37.75M | $0.47 |
| 2019 | $189.39M | $40.56M | $0.52 |
| 2018 | $154.58M | $28.59M | $0.35 |
| 2017 | $107.52M | $-91.47M | $-1.50 |
| 2016 | $16.69M | $-18.44M | $-0.35 |
| 2015 | $11.84M | $-10.89M | $-0.22 |
| 2014 | $25.76M | $-7.01M | $-0.14 |
| 2013 | $9.45M | $-20.80M | $-0.45 |
| 2012 | $14.04M | $-31.86M | $-3.50 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.06
- Implied price
- $1.06
- Return from $9.75
- -35.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $0.53 — -94.6% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | -46.3% | -43.9% | -41.8% | -40.0% | -38.4% |
| 3.0% | -43.6% | -41.0% | -38.8% | -36.9% | -35.2% |
| 8.0% | -40.9% | -38.2% | -35.9% | -33.9% | -32.1% |
| 13.0% | -38.1% | -35.3% | -32.9% | -30.8% | -28.9% |
| 18.0% | -35.4% | -32.4% | -29.9% | -27.7% | -25.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
120+100.00%Social Signal Score
Mentions (4)
- Newsseekingalpha.com·6d ago·Positive
Pharming Group: Viable Contrarian Buy If Ruconest Stabilizes RUCONEST is Pharming Group's main revenue source today. This asset has already shown a sequential sales rebound that makes me more optimistic. However, RUCONEST still has oral competition that could make stabilizing that revenue bleed more challenging. Still, my bull case assumes RUCONEST's issues are manageable. If so, that could buy time for Joenja to grow and improve the business mix.
View source ↗ - Newsglobenewswire.com·7d ago·Neutral
Pharming announces CEO transition Leiden, the Netherlands, September 29, 2026 : Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the Board of Directors and Fabrice Chouraqui have mutually agreed that Mr. Chouraqui will step down as Chief Executive Officer and Executive Director, with immediate effect.
View source ↗ - Newsglobenewswire.com·10d ago·Negative
…o 11 years with APDS weighing at least 27 kg PDUFA target action date of January 30, 2027 Leiden, the Netherlands, September 25, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) seeking approval for lower doses of Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3K…
View source ↗ - Newsglobenewswire.com·24d ago·Negative
…ho weigh at least 27kg Newly approved Joenja doses are expected to be available in October Leiden, the Netherlands, September 11, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for 40 mg and 50 mg twice-daily dosing of Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta…
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $0.12 per share
Typical surprise +100.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$0.02 vs $0.06miss
- Thu, May 7$-0.07 vs $0.05miss
- Thu, Mar 12$0.07 vs $0.01beat
- Thu, Nov 6$0.10 vs $0.05beat
- Thu, Jul 31$0.06 vs $-0.10beat
- Thu, May 8$-0.22 vs $-0.03miss
Estimates and results for PHAR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PHAR officers and directors.
No open-market trades in the recent filings. All 1 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
1 further Form 4 entry is share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PHAR.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.